Published in Medical Imaging Law Weekly, April 14th, 2009
"The secondary objective was to define the optimal dose of the second-generation contrast agent to routinely use in the CEUS examinations for endoleak detection. The study enrolled 84 patients with unruptured AAA who were treated with EVAR and...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Imaging Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.